https://www.aigom.it/wp-content/uploads/2025/03/art4.3.png1242960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-04 08:49:132025-03-04 08:58:47FINAL, 10-YEAR OUTCOMES WITH NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA.
https://www.aigom.it/wp-content/uploads/2025/02/25.02.png1353960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-02-25 08:25:392025-02-25 08:25:39BREAST CANCER BRAIN METASTASIS: A COMPREHENSIVE REVIEW.
https://www.aigom.it/wp-content/uploads/2025/02/ART18.2.png1201960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-02-18 08:50:152025-02-18 08:50:15SURVIVAL WITH CEMIPLIMAB IN RECURRENT CERVICAL CANCER.
https://www.aigom.it/wp-content/uploads/2025/02/ART11.2.png1471960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-02-11 08:40:452025-02-11 08:40:45DAROLUTAMIDE IN COMBINATION WITH ANDROGEN-DEPRIVATION THERAPY IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER FROM THE PHASE III ARANOTE TRIAL.
https://www.aigom.it/wp-content/uploads/2025/02/ART.04.02.png1254960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-02-03 09:18:082025-02-03 09:18:08CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN NON-SMALL CELL LUNG CANCER WITH PD-L1≥ 1 %: A SUBGROUP ANALYSIS FROM THE EMPOWER-LUNG 3 PART 2 TRIAL.
https://www.aigom.it/wp-content/uploads/2025/01/ART28.01.png1242960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-01-29 06:57:012025-01-29 06:57:01RIBOCICLIB PLUS ENDOCRINE THERAPY IN EARLY BREAST CANCER.
https://www.aigom.it/wp-content/uploads/2025/01/ART14.1.png1222960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-01-13 18:20:432025-01-13 18:20:43FINAL RESULTS FOR ADJUVANT DABRAFENIB PLUS TRAMETINIB IN STAGE III MELANOMA
https://www.aigom.it/wp-content/uploads/2025/01/ART.07.01.png1148960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-01-06 13:58:302025-01-06 13:58:30HORMONAL CONTRACEPTION AND BREAST CANCER RISK FOR CARRIERS OF GERMLINE MUTATIONS IN BRCA1 AND BRCA2
https://www.aigom.it/wp-content/uploads/2024/12/art.10.12.png1084960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-12-09 15:42:272024-12-09 15:42:27OMISSION OF RADIOTHERAPY AFTER BREAST-CONSERVING SURGERY FOR WOMEN WITH BREAST CANCER WITH LOW CLINICAL AND GENOMIC RISK: 5-YEAR OUTCOMES OF IDEA
